NGS-Based MRD Testing Services for Hematologic Malignancies
Contract Overview
Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.
AI Contract Overview
The contract solicits qualified providers to deliver FDA-cleared next-generation sequencing-based minimal residual disease testing services for hematologic malignancies using bone marrow, blood, and FFPE specimens. The scope encompasses comprehensive analysis, clinical interpretation, and detailed reporting of MRD status to support patient management decisions. Testing must adhere strictly to regulatory standards for clinical use and be performed with validated, high-sensitivity NGS methodologies capable of detecting residual cancer cells at low levels across diverse hematologic cancer types. Performance of services is to be conducted in Portland, Oregon, with a response deadline of August 10, 2026, and the contract is classified as a subcontract under NAICS code 621511. While no set-aside provisions are specified, the contracting office is the Department of Veterans Affairs through its 260-NETWORK Contract Office 20. The requirement emphasizes reliability, accuracy, and timeliness in results delivery, ensuring diagnostic integrity for clinical decision-making in veteran healthcare settings.
General Info
Agency
NAICS
Place of Performance
Portland, OR, 97239, USASet-Aside
Documents
(0)AI Contract Breakdown
Uniform Contract FormatNo contract breakdown available.
Cannot generate Contract Breakdown because no documents were found from this contract's source.
Timeline
Response Deadline
Organization & Contact Information
Full Description
Similar Contracts
Same NAICS industry code
More opportunities from Department Of Veterans Affairs → 260-NETWORK Contract Office 20 (36C260)
Same awarding agency
